由強生(JNJ.US)分拆消費者產品企業Kenvue(KVUE.US)傳洽售部分護膚及化妝品牌
《路透》引述消息報道,由強生(JNJ.US)2023年分拆的消費者健康產品企業Kenvue(KVUE.US)尋求出售旗下部分護膚及化妝品牌。以剔除表現較弱業務以集中核心產品,涉及Clean & Clear、Maui Moisture、Neostrata、德國嬰兒護理品牌Bebe及日本品牌Dr.Ci:Labo。
消息指,公司計劃保留Neutrogena及Aveeno等較大型品牌,又指出售品牌組合或有改變,亦不保證達成交易協議。高盛正就有關出售提供協助。
消息又指,擬售品牌銷售額逾5億美元,去年公司整體收入為155億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.